GeneDx Holdings Corp (NASDAQ:WGS) has a beta value of 2.08 and has seen 1.69 million shares traded in the recent trading session. The company, currently valued at $2.74B, closed the recent trade at $99.72 per share which meant it gained $23.37 on the day or 30.61% during that session. The WGS stock price is 0.85% off its 52-week high price of $98.87 and 95.65% above the 52-week low of $4.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.57 million shares traded. The 3-month trading volume is 801.39K shares.
The consensus among analysts is that GeneDx Holdings Corp (WGS) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.06.
GeneDx Holdings Corp (NASDAQ:WGS) trade information
Sporting 30.61% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the WGS stock price touched $99.72 or saw a rise of 5.76%. Year-to-date, GeneDx Holdings Corp shares have moved 29.74%, while the 5-day performance has seen it change 46.32%. Over the past 30 days, the shares of GeneDx Holdings Corp (NASDAQ:WGS) have changed 46.09%. Short interest in the company has seen 2.14 million shares shorted with days to cover at 2.54.
Wall Street analysts have a consensus price target for the stock at $52, which means that the shares’ value could drop -91.77% from the levels at last check today. The projected low price target is $34.0 while the price target rests at a high of $70.0. In that case, then, we find that the latest price level in today’s session is 29.8% off the targeted high while a plunge would see the stock lose 65.9% from the levels at last check today.
GeneDx Holdings Corp (WGS) estimates and forecasts
The company’s shares have gained 203.19% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 10.91%.
6 analysts offering their estimates for the company have set an average revenue estimate of 78M for the current quarter. 6 have an estimated revenue figure of 83.15M for the next ending quarter. Year-ago sales stood 62.42M and 70.51M respectively for this quarter and the next, and analysts expect sales will grow by 24.96% for the current quarter and 10.91% for the next.
Earnings growth for 2025 is a modest 119.67% while over the next 5 years, the company’s earnings are expected to increase by 119.30%.
WGS Dividends
GeneDx Holdings Corp is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
GeneDx Holdings Corp (NASDAQ:WGS)’s Major holders
Insiders own 18.85% of the company shares, while shares held by institutions stand at 86.62% with a share float percentage of 106.74%. Investors are also buoyed by the number of investors in a company, with GeneDx Holdings Corp having a total of 249.0 institutions that hold shares in the company. The top two institutional holders are CASDIN CAPITAL, LLC with over 3.53 million shares worth more than $92.18 million. As of 2024-06-30, CASDIN CAPITAL, LLC held 13.2482% of shares outstanding.
The other major institutional holder is CORVEX MANAGEMENT LP, with the holding of over 2.47 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.66 million and represent 9.2937% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Alger Small Cap Focus Fund and Vanguard Total Stock Market Index Fund. As of Oct 31, 2024, the former fund manager holds about 1.68% shares in the company for having 461.76 shares of worth $46.54 million while later fund manager owns 410.78 shares of worth $41.4 million as of Sep 30, 2024, which makes it owner of about 1.50% of company’s outstanding stock.
